Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)

NCT03154047 is registered in ClinicalTrials.gov with Prothena Biosciences Ltd. as lead sponsor.

NCT NCT03154047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03154047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Lead sponsor
Prothena Biosciences Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
June 14, 2017
Completion date
May 30, 2018
Enrollment
80 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis